BioVaxys Technology (TSE:BIOV) has released an update.
BioVaxys Technology Corp. has entered a collaborative agreement to develop a new therapy for life-threatening food allergies using its DPX platform. Partnering with AP Visionaries, Inc. and The Schroeder Allergy and Immunology Research Institute, they aim to alleviate risks associated with peanut and other nut allergies. With the global peanut allergy treatment market projected to reach USD 1.01 billion by 2030, BioVaxys’s innovative approach could meet a significant unmet medical need.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
